Court deadline looms in Edwards Lifesciences class action suit; Gout test launches in Europe;

@FierceMedDev: Cheney worried defibrillator was vulnerable to hacking from terrorists. Item | Follow @FierceMedDev

@MarkHFierce: Kona Medical, a 2013 Fierce 15 winner, drew in $10M in new funding to hit China with its renal denervation device. Release | Story | Follow @MarkHFierce

@MichaelGFierce: ICYMI: AstraZeneca teams with Taris to research bladder cancer delivery device. Story from FierceDrugDelivery | Follow @MichaelGFierce

> Those wishing to sue Edwards Lifesciences ($EW) for allegedly inflating sales projections of its Sapien heart valve have a major court deadline coming up on Nov. 18. Item

> Sapiens Steering Brain Stimulation, a German/Dutch company focused on developing next-generation brain stimulation devices, has brought on a new CEO. Item

> U.K. regulators have raised standards for hip implants. Story (sub. req.)

> Since 2005, nearly 800 patients have had surgical instruments left inside them after a procedure. Story

> A researcher at Harvard Medical School and colleagues have come up with an implantable gel designed to treat diabetes that produces a compound to stimulate insulin secretion. It contains genetically modified light-sensitive cells. Item

> Boulder Diagnostics is rolling out its new in vitro diagnostic blood for gout in Europe. Item

Biotech News

@FierceBiotech: ICYMI last week: FierceMedicalDevices' 2013 Fierce 15. Feature | Follow @FierceBiotech

@JohnCFierce: Latest biotech IPO tally: 39 done, 15 in the queue--report updated with stock performance as of last Thursday. Feature | Follow @JohnCFierce

@DamianFierce: Quintiles is shuttering an early-phase Indian facility as regulatory hurdles make times tough. FierceCRO article | Follow @DamianFierce

@EmilyMFierce: FierceBiotech is looking for an associate editor. Details here | Follow @EmilyMFierce

> Iroko gets a thumbs-up from FDA on lower-dose NSAID. Item

> Novartis advances rival CDK 4/6 cancer drug to Pfizer's palbociclib. Article

> TetraLogic joins IPO rush with $103.5M offering to fuel cancer drug R&D. News

> Lilly's Lechleiter isn't budging from stand-alone $5B R&D strategy--yet. Story

> Actelion wins crucial FDA approval for next-gen lung disease drug Opsumit. News

Pharma News

@FiercePharma:  ICYMI, most popular special report this weekend: Top 15 Drug Launch Superstars | Follow @FiercePharma

@EricPFierce: Novartis' Sandoz is the 2nd largest generics maker in the world. It targets biosimilars to stay there. More | Follow @EricPFierce

@CarlyHFierce: We now present: Top 10 generics makers by 2012 revenue. Special report | Follow @CarlyHFierce

> Regeneron and Bayer's Eylea turns out positive BRVO trial data. Story

> India's bargain-priced cancer drugs lure Chinese smugglers. Article

> Japan's Eisai says U.K. cost watchdogs must open up--or else. Report

CRO News

> WuXi is first in China with CLIA-OK genomics lab. Item

> Novella teams with Scioderm for 'breakthrough' drug. More

> DrugDev picks up CFS Clinical for trial software. Story

> Aenova snags Haupt to boost CMO presence. News

> Clinlogix buys German CRO with eye on Euro demand. Article

Biotech IT News

> Pfizer and Roche back protein shape change monitoring startup. Story

> Deloitte unveils another EHR-driven software tool. News

> Statisticians fret over misuse of data-crunching software. More

> Veeva stock soars following successful IPO. Article

> Roche to shutter 454, 6 years after buying NGS business. Story

Suggested Articles

BD will begin working with Babson Diagnostics to help bring its lab-quality device for collecting blood from capillaries into retail pharmacies.

The former CEO of the molecular testing company Foundation Medicine, Troy Cox, has been named chairman of the Swiss big data firm Sophia Genetics.

Researchers at MIT used a machine-learning algorithm to uncover the potent antibiotic properties hiding within an old small-molecule candidate.